Trial Profile

An early access program (AAC) for LUMEVOQ in France

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenadogene nolparvovec (Primary)
Indications Leber's hereditary optic atrophy
Focus Therapeutic Use

Most Recent Events

20 Jun 2025 New trial record
12 Jun 2025 According to GenSight Biologics media release, the company announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ upon approval of a dose-ranging clinical study.
12 Jun 2025 According to GenSight Biologics media release, AAC program is targeted to open in Q4 2025 at the latest.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com